Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)
Sue S Yom, Pedro Torres-Saavedra, Jimmy J Caudell, John N Waldron, Maura L Gillison, Ping Xia, Minh T Truong, Christina Kong, Richard Jordan, Rathan M Subramaniam, Min Yao, Christine H Chung, Jessica L Geiger, Jason W Chan, Brian O'Sullivan, Dukagjin M Blakaj, Loren K Mell, Wade L Thorstad, Christopher U Jones, Robyn N Banerjee, Christopher Lominska, Quynh-Thu Le, Sue S Yom, Pedro Torres-Saavedra, Jimmy J Caudell, John N Waldron, Maura L Gillison, Ping Xia, Minh T Truong, Christina Kong, Richard Jordan, Rathan M Subramaniam, Min Yao, Christine H Chung, Jessica L Geiger, Jason W Chan, Brian O'Sullivan, Dukagjin M Blakaj, Loren K Mell, Wade L Thorstad, Christopher U Jones, Robyn N Banerjee, Christopher Lominska, Quynh-Thu Le
Abstract
Purpose: Reducing radiation treatment dose could improve the quality of life (QOL) of patients with good-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma (OPSCC). Whether reduced-dose radiation produces disease control and QOL equivalent to standard chemoradiation is not proven.
Patients and methods: In this randomized, phase II trial, patients with p16-positive, T1-T2 N1-N2b M0, or T3 N0-N2b M0 OPSCC (7th edition staging) with ≤ 10 pack-years of smoking received 60 Gy of intensity-modulated radiation therapy (IMRT) over 6 weeks with concurrent weekly cisplatin (C) or 60 Gy IMRT over 5 weeks. To be considered for a phase III study, an arm had to achieve a 2-year progression-free survival (PFS) rate superior to a historical control rate of 85% and a 1-year mean composite score ≥ 60 on the MD Anderson Dysphagia Inventory (MDADI).
Results: Three hundred six patients were randomly assigned and eligible. Two-year PFS for IMRT + C was 90.5% rejecting the null hypothesis of 2-year PFS ≤ 85% (P = .04). For IMRT, 2-year PFS was 87.6% (P = .23). One-year MDADI mean scores were 85.30 and 81.76 for IMRT + C and IMRT, respectively. Two-year overall survival rates were 96.7% for IMRT + C and 97.3% for IMRT. Acute adverse events (AEs) were defined as those occurring within 180 days from the end of treatment. There were more grade 3-4 acute AEs for IMRT + C (79.6% v 52.4%; P < .001). Rates of grade 3-4 late AEs were 21.3% and 18.1% (P = .56).
Conclusion: The IMRT + C arm met both prespecified end points justifying advancement to a phase III study. Higher rates of grade ≥ 3 acute AEs were reported in the IMRT + C arm.
Trial registration: ClinicalTrials.gov NCT02254278.
Figures
References
- Chaturvedi AK Engels EA Pfeiffer RM, et al. : Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294-4301, 2011
- D'Souza G Kreimer AR Viscidi R, et al. : Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944-1956, 2007
- Herrero R: Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95:1772-1783, 2003
- Fakhry C Westra WH Li S, et al. : Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261-269, 2008
- Fakhry C Zhang Q Nguyen-Tan PF, et al. : Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 32:3365-3373, 2014
- Aggarwal P Zaveri JS Goepfert RP, et al. : Swallowing-related outcomes associated with late lower cranial neuropathy in long-term oropharyngeal cancer survivors: Cross-sectional survey analysis. Head Neck 41:3880-3894, 2019
- Adelstein DJ Li Y Adams GL, et al. : An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
- Bourhis J Sire C Graff P, et al. : Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial. Lancet Oncol 13:145-153, 2012
- Trotti A Pajak TF Gwede CK, et al. : TAME: Development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 8:613-624, 2007
- Machtay M Moughan J Trotti A, et al. : Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol 26:3582-3589, 2008
- Kimple RJ Smith MA Blitzer GC, et al. : Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res 73:4791-4800, 2013
- Rieckmann T Tribius S Grob TJ, et al. : HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother Oncol 107:242-246, 2013
- Chen AM Felix C Wang PC, et al. : Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: A single-arm, phase 2 study. Lancet Oncol 18:803-811, 2017
- Chera BS Amdur RJ Tepper JE, et al. : Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cancer 124:2347-2354, 2018
- O'Sullivan B Huang SH Perez-Ordonez B, et al. : Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol 103:49-56, 2012
- Hall SF Liu FF O'Sullivan B, et al. : Did the addition of concurrent chemotherapy to conventional radiotherapy improve survival for patients with HPV+ve and HPV−ve oropharynx cancer? A population-based study. Br J Cancer 117:1105-1112, 2017
- Eisbruch A Harris J Garden AS, et al. : Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 76:1333-1338, 2010
- Beitler JJ Switchenko JM Dignam JJ, et al. : Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx. Cancer 125:704-711, 2019
- Ang KK Harris J Wheeler R, et al. : Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
- Marur S Li S Cmelak AJ, et al. : E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx-ECOG-ACRIN Cancer Research Group. J Clin Oncol 35:490-497, 2017
- Jordan RC Lingen MW Perez-Ordonez B, et al. : Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 36:945-954, 2012
- Bhide SA Gulliford S Kazi R, et al. : Correlation between dose to the pharyngeal constrictors and patient quality of life and late dysphagia following chemo-IMRT for head and neck cancer. Radiother Oncol 93:539-544, 2009
- Gillespie MB Brodsky MB Day TA, et al. : Swallowing-related quality of life after head and neck cancer treatment. Laryngoscope 114:1362-1367, 2004
- Ringash J O'Sullivan B Bezjak A, et al. : Interpreting clinically significant changes in patient-reported outcomes. Cancer 110:196-202, 2007
- Grossman SA Schreck KC Ballman K, et al. : Point/counterpoint: Randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma. Neurooncol 19:469-474, 2017
- Gillison ML Trotti AM Harris J, et al. : Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial. Lancet 393:40-50, 2019
- Mehanna H Robinson M Hartley A, et al. : Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial. Lancet 393:51-60, 2019
- Nichols AC Theurer J Prisman E, et al. : Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): An open-label, phase 2, randomised trial. Lancet Oncol 20:1349-1359, 2019
- Guo T Qualliotine JR Ha PK, et al. : Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer: Surgical salvage for recurrent OPSCC. Cancer 121:1977-1984, 2015
- Patel SN Cohen MA Givi B, et al. : Salvage surgery for locally recurrent oropharyngeal cancer: Salvage surgery for locally recurrent oropharyngeal cancer. Head Neck 38:E658-E664, 2016
- Noronha V Joshi A Patil VM, et al. : Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: A phase III randomized noninferiority trial. J Clin Oncol 36:1064-1072, 2018
- Bauml JM Vinnakota R Anna Park YH, et al. : Cisplatin every 3 weeks versus weekly with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck. J Natl Cancer Inst 111:490-497, 2019
- Liang H Xia WX Lv X, et al. : Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979). J Clin Oncol 35, 2017. (suppl; abstr 6006)
- Szturz P Wouters K Kiyota N, et al. : Low-dose vs. High-dose cisplatin: Lessons learned from 59 chemoradiotherapy trials in head and neck cancer. Front Oncol 9:86, 2019
- Ang KK Zhang Q Rosenthal DI, et al. : Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 32:2940-2950, 2014
- Strumberg D Brügge S Korn MW, et al. : Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 13:229-236, 2002
- Nonnekens J, Hoeijmakers JH: After surviving cancer, what about late life effects of the cure? EMBO Mol Med 9:4-6, 2017
- Forastiere AA Zhang Q Weber RS, et al. : Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31:845-852, 2013
- Ma DJ Price KA Moore EJ, et al. : Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma. J Clin Oncol 37:1909-1918, 2019
- Swisher-McClure S Lukens JN Aggarwal C, et al. : A phase 2 trial of alternative volumes of oropharyngeal irradiation for de-intensification (AVOID): Omission of the resected primary tumor bed after transoral robotic surgery for human papilloma virus-related squamous cell carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys 20:1349-1359, 2019
- Seiwert T Melotek JM Foster CC, et al. : OPTIMA—a phase 2 trial of induction chemotherapy response-stratified radiation therapy dose and volume de-escalation for HPV+ oropharyngeal cancer: Efficacy, toxicity, and HPV subtype Analysis. Int J Radiat Oncol Biol Phys 100:1309, 2018
- National Cancer Institute : NCTN/NCORP Data Archive,
Source: PubMed